Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCC

Name: Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCC
Uploaded: 2017-07-27T02:15:00.000Z
Description: Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

July 26, 2017

Michael B. Atkins, MD

Video

In Partnership With:

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).